MAPK1 and neoplasm: These drugs disrupt the MAPK/ERK signaling pathway that regulates cytoskeletal dynamics and cell junction integrity, leading to increased vascular permeability and potential risks such as enhanced metastatic potential of tumor cells and complications related to vascular leakage.